For the Inventor, By the Inventor

Enter inventor name

Moraga, CA, United States of America

Jiong Lan

USPTO Granted Patents = 34 (Patent Applications = 7)

CIPO Patents = 2

EPO Patents = 12 (Patent Applications = 7)

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 256(Granted Patents)

Location History:

San Diego, CA (US) (2010 - 2011)
Morago, CA (US) (2013)
Emeryville, CA (US) (2009 - 2014)
Moraga, CA (US) (2009 - 2015)
Jiangsu, CN (2016)
Shanghai, CN (2016 - 2021)

Company Filing History:

16 out of 3,923

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Yangtze River Pharmaceutical Group Co., Ltd.

4. 3 out of 159

Jiangsu Hengrui Medicine Company Ltd.

5. 3 out of 100

Shanghai Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

7. 1 out of 245

Novartis Vaccines & Diagnostics, Gmbh

8. 1 out of 305

Neurogen Corporation

where one patent can have more than one assignee

Years Active: 2009-2021

where 'Filed Patents' based on already Granted Patents

34 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11174254 - Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof (2021-11-16),

2. 11155546 - 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof (2021-10-26),

3. 11104664 - 4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof (2021-08-31),

4. 10815197 - N-sulfonyl benzamides as voltage-gated sodium channel inhibitors (2020-10-27),

5. 10793549 - Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof (2020-10-06),

6. 10577346 - Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof (2020-03-03),

7. 10561646 - EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof (2020-02-18),

8. 10435400 - 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom (2019-10-08),

9. 10428074 - Pyrrole heteroaryl ring derivative and method of use thereof (2019-10-01),

10. 10100047 - Piperidine derivatives as orexin receptor antagonist (2018-10-16),

11. 10085983 - Azabicyclo derivatives, process for preparation thereof and medical use thereof (2018-10-02),

12. 9890168 - 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof (2018-02-13),

13. 9879008 - 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof (2018-01-30),

14. 9637484 - Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof (2017-05-02),

15. 9527851 - Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof (2016-12-27),

Title: Unveiling the Innovations of Inventor Jiong Lan from Moraga, CA

Introduction:

In the realm of inventiveness, Jiong Lan has emerged as a prominent figure with a trail of groundbreaking patents in the pharmaceutical field. Hailing from Moraga, CA, he stands as a testament to ingenuity and relentless pursuit of scientific advancement.

Latest Patents:

Jiong Lan's recent patents showcase his prowess in chemistry and pharmacology. His invention of Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivatives and their applications in pharmaceuticals signify a significant contribution to the medical industry. Additionally, his work on 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives underscores his innovative spirit and commitment to enhancing therapeutic interventions.

Career Highlights:

Having worked in esteemed companies such as Novartis AG and Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Jiong Lan has honed his expertise and garnered invaluable experience in the pharmaceutical sector. His strategic insights and scientific acumen have led to the development of novel compounds with promising potential for medical applications.

Collaborations:

Collaborating with visionary coworkers like Fusheng Zhou and Hengyuan Lang, Jiong Lan has fostered a culture of innovation and collaboration. Together, they have synergized their skills and knowledge to push the boundaries of pharmaceutical research, resulting in impactful advancements that elevate the standard of healthcare.

Conclusion:

In conclusion, Jiong Lan's inventive journey epitomizes the transformative power of innovation in the realm of pharmaceuticals. His dedication to pioneering novel compounds and pushing the frontiers of pharmacology underscores his commitment to shaping a healthier and brighter future for all.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…